Brokerages forecast that Agile Therapeutics Inc (NASDAQ:AGRX) will post earnings per share of ($0.11) for the current quarter, according to Zacks. Zero analysts have issued estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.13) to ($0.09). Agile Therapeutics reported earnings per share of ($0.16) during the same quarter last year, which suggests a positive year-over-year growth rate of 31.3%. The company is scheduled to issue its next earnings results on Friday, August 2nd.
According to Zacks, analysts expect that Agile Therapeutics will report full-year earnings of ($0.49) per share for the current financial year, with EPS estimates ranging from ($0.64) to ($0.39). For the next year, analysts expect that the business will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.76) to $0.11. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02).
In related news, CEO Alfred Altomari acquired 25,000 shares of Agile Therapeutics stock in a transaction on Monday, March 25th. The shares were purchased at an average cost of $1.54 per share, for a total transaction of $38,500.00. Following the purchase, the chief executive officer now directly owns 238,568 shares of the company’s stock, valued at approximately $367,394.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Abhijeet J. Lele acquired 20,000 shares of Agile Therapeutics stock in a transaction on Friday, March 29th. The shares were bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the director now directly owns 37,949 shares in the company, valued at $58,441.46. The disclosure for this purchase can be found here. Corporate insiders own 8.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of AGRX. Perceptive Advisors LLC bought a new position in Agile Therapeutics during the 1st quarter valued at $12,724,000. Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 54.3% in the 3rd quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 260.7% in the 4th quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares during the last quarter. Advisor Group Inc. lifted its position in shares of Agile Therapeutics by 716.7% in the 1st quarter. Advisor Group Inc. now owns 147,000 shares of the specialty pharmaceutical company’s stock worth $222,000 after buying an additional 129,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Agile Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the last quarter. Hedge funds and other institutional investors own 21.59% of the company’s stock.
Shares of AGRX stock opened at $1.41 on Friday. The firm has a market capitalization of $62.12 million, a PE ratio of -2.43 and a beta of 0.45. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01. Agile Therapeutics has a twelve month low of $0.23 and a twelve month high of $1.70.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Further Reading: Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.